Abstract
Background: Valsartan/hydrochlorothiazide is a combination of an angiotensin II receptor antagonist and diuretic indicated for hypertensive patients as initial therapy and those not controlled on monotherapy. Objective: To evaluate the pharmacokinetic, pharmacodynamic and clinical efficacy of valsartan/hydrochlorothiazide in hypertension therapy and other cardiovascular outcomes. Methods: Review of current literature. Results: Valsartan/ hydrochlorothiazide has been shown to be superior to its individual components in randomized controlled studies of patients with moderate-to-severe hypertension and in patients who did not respond to monotherapy. When compared to amlodipine, valsartan/hydrochlorothiazide was shown to have a similar rate of the combined outcome of morbidity and mortality. Valsartan/ hydrochlorothiazide has also been studied in specific patient populations, such as diabetics, obese, elderly, black hypertensives and hypertensives with further cardiovascular risk factors, and has been shown to be efficacious in such populations. Conclusion: Valsartan/hydrochlorothiazide has been shown to be an efficacious fixed-dose combination antihypertensive agent that is well tolerated with few side effects.
| Original language | English |
|---|---|
| Pages (from-to) | 1125-1134 |
| Number of pages | 10 |
| Journal | Expert Opinion on Drug Metabolism and Toxicology |
| Volume | 5 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2009 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Toxicology
- Pharmacology
Cite this
Valsartan/hydrochlorothiazide : Pharmacology and clinical efficacy. / Kondrack, Robyn; Mohiuddin, Syed M.
In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, No. 9, 09.2009, p. 1125-1134.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Valsartan/hydrochlorothiazide
T2 - Pharmacology and clinical efficacy
AU - Kondrack, Robyn
AU - Mohiuddin, Syed M.
PY - 2009/9
Y1 - 2009/9
N2 - Background: Valsartan/hydrochlorothiazide is a combination of an angiotensin II receptor antagonist and diuretic indicated for hypertensive patients as initial therapy and those not controlled on monotherapy. Objective: To evaluate the pharmacokinetic, pharmacodynamic and clinical efficacy of valsartan/hydrochlorothiazide in hypertension therapy and other cardiovascular outcomes. Methods: Review of current literature. Results: Valsartan/ hydrochlorothiazide has been shown to be superior to its individual components in randomized controlled studies of patients with moderate-to-severe hypertension and in patients who did not respond to monotherapy. When compared to amlodipine, valsartan/hydrochlorothiazide was shown to have a similar rate of the combined outcome of morbidity and mortality. Valsartan/ hydrochlorothiazide has also been studied in specific patient populations, such as diabetics, obese, elderly, black hypertensives and hypertensives with further cardiovascular risk factors, and has been shown to be efficacious in such populations. Conclusion: Valsartan/hydrochlorothiazide has been shown to be an efficacious fixed-dose combination antihypertensive agent that is well tolerated with few side effects.
AB - Background: Valsartan/hydrochlorothiazide is a combination of an angiotensin II receptor antagonist and diuretic indicated for hypertensive patients as initial therapy and those not controlled on monotherapy. Objective: To evaluate the pharmacokinetic, pharmacodynamic and clinical efficacy of valsartan/hydrochlorothiazide in hypertension therapy and other cardiovascular outcomes. Methods: Review of current literature. Results: Valsartan/ hydrochlorothiazide has been shown to be superior to its individual components in randomized controlled studies of patients with moderate-to-severe hypertension and in patients who did not respond to monotherapy. When compared to amlodipine, valsartan/hydrochlorothiazide was shown to have a similar rate of the combined outcome of morbidity and mortality. Valsartan/ hydrochlorothiazide has also been studied in specific patient populations, such as diabetics, obese, elderly, black hypertensives and hypertensives with further cardiovascular risk factors, and has been shown to be efficacious in such populations. Conclusion: Valsartan/hydrochlorothiazide has been shown to be an efficacious fixed-dose combination antihypertensive agent that is well tolerated with few side effects.
UR - http://www.scopus.com/inward/record.url?scp=70249083819&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70249083819&partnerID=8YFLogxK
U2 - 10.1517/17425250903136730
DO - 10.1517/17425250903136730
M3 - Review article
C2 - 19689218
AN - SCOPUS:70249083819
VL - 5
SP - 1125
EP - 1134
JO - Expert Opinion on Drug Metabolism and Toxicology
JF - Expert Opinion on Drug Metabolism and Toxicology
SN - 1742-5255
IS - 9
ER -